2023-505871-63-00
CTIS ↗
OP-1250-301
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy
pharma · Hormone Receptor Positive Breast Carcinoma · ER+, HER2- Advanced Breast Cancer · OLMA
Olema Pharmaceuticals
Olema Pharmaceuticals trial registry — 9 ClinicalTrials.gov studies with program phase, status, and indication context.
Chennai, IN HQ
2 Employees
Public company Type
OLMA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Chennai, IN
- Employees
- 2
- Programs
- 7
- Drugs
- 17
- Patents
- 8
Olema Pharmaceuticals clinical trials
Registry index of 9 ClinicalTrials.gov studies linked to Olema Pharmaceuticals programs — each row shows trial ID, program name, phase, status, and indication.
Olema Pharmaceuticals trial registry — 9 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Olema Pharmaceuticals.
-
OP-1250-301 — Phase 3
Clinical update -
OP-1250-302 — Phase 3
Clinical update -
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors — Phase 1
Clinical update -
OP-1250 — Phase 2
Clinical update -
Palazestrant — Phase 3
Clinical update -
OP-3136 — Phase 1
Clinical update -
Palazestrant — Phase 1
Clinical update
Trial registry
-
-
CTIS ↗ - 2025-523686-15-00CTIS ↗
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid Tumors
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗